Testosterone Enanthate vs Undecanoate: Pharmacokinetics, Injection Protocol, and Blood Test Timing

Testosterone enanthate (Test E) and injectable testosterone undecanoate (brand names Nebido in Europe and Australia, Aveed in the United States) are both intramuscular testosterone formulations, but they differ dramatically in pharmacokinetics, injection schedule, and clinical management.

Testosterone enanthate is a medium-acting ester with a half-life of approximately 4 to 5 days. It requires weekly or twice-weekly injections and reaches stable steady-state levels in approximately 3 weeks. It is the most widely used testosterone preparation globally for both TRT and performance enhancement.

Testosterone undecanoate (injectable) is an ultra-long-acting ester with a half-life of approximately 20 to 21 days. It is designed specifically for TRT, where its extended release allows injections every 10 to 14 weeks once steady state is achieved. It is not used in bodybuilding for performance enhancement because the inability to rapidly adjust dose or discontinue makes it unsuitable for cycling.

The fundamental trade-off is convenience versus control: undecanoate offers fewer injections per year (4 to 5 vs. 52 to 104 for enanthate), but at the cost of very long loading periods, less precise dose adjustment, and blood test timing that must account for extreme pharmacokinetic variability.

Note: oral testosterone undecanoate (Andriol, Jatenzo) has a completely different pharmacokinetic profile and is not covered in this comparison. This comparison covers injectable testosterone undecanoate only.

Ester chain length and half-life:

• Enanthate: 7-carbon ester, half-life approximately 4 to 5 days
• Undecanoate: 11-carbon ester, half-life approximately 20 to 21 days
• The undecanoate ester is roughly 4 to 5 times longer-acting than enanthate

Peak serum levels:

• Enanthate: peaks at 24 to 48 hours after injection, then declines over the following 5 to 7 days
• Undecanoate: peaks much later, at approximately 7 days post-injection (range 3 to 14 days), due to the slow release from the oil depot and the long ester cleavage time

Injection frequency:

• Enanthate: weekly or twice-weekly (52 to 104 injections per year for TRT)
• Undecanoate: loading injections at week 0 and week 6, then maintenance injections every 10 to 14 weeks (4 to 5 injections per year for maintenance)

Loading and steady-state timeline:

• Enanthate: reaches steady state in approximately 3 weeks (5 half-lives of 4 to 5 days)
• Undecanoate: requires an initial loading phase with injections at week 0 and week 6. True pharmacokinetic steady state takes approximately 30 weeks (5 half-lives of 20 to 21 days) to achieve. This extended loading period means testosterone levels are variable and often suboptimal for the first 6 to 9 months of treatment.

Injection volume and site:

• Enanthate: typically 0.5 to 2 mL per injection, intramuscular or subcutaneous, widely flexible in injection sites
• Undecanoate (Nebido/Aveed): 4 mL (1,000 mg) injection, strictly intramuscular, large volume requires slow administration (over 2 minutes minimum). In the US, Aveed carries an FDA-required Risk Evaluation and Mitigation Strategy (REMS) due to the risk of pulmonary oil microembolism.

Dose flexibility:

• Enanthate: dose can be adjusted immediately at any injection. Effects of dose changes are felt within 1 to 2 weeks.
• Undecanoate: dose adjustments are made by shifting the inter-injection interval (injecting slightly earlier or later). Because of the long half-life, the full effect of any adjustment is not apparent for many weeks.

Blood draw timing for accurate readings:

• Enanthate: draw at trough (6 to 7 days after weekly injection, or immediately before next injection on twice-weekly protocol). Highly reproducible when timed consistently.
• Undecanoate: midpoint between injections is the standard reference point. For a 12-week interval, draw at approximately week 6 post-injection. Trough levels (just before the next scheduled injection at week 10 to 14) reflect the nadir and help determine if the interval needs adjusting. Both mid-point and trough measurements are clinically useful and should be labelled with exact timing.

Aromatisation pattern:

• Enanthate: relatively predictable peak-to-trough oestradiol variation following the weekly injection cycle
• Undecanoate: oestradiol tracks the slow, broad release curve. The risk of acute oestrogen spikes is lower, but managing oestradiol over a 10 to 14 week interval with any aromatase inhibitor is complex and generally avoided by most clinicians

Choose testosterone enanthate for:

• Standard TRT where dose flexibility and predictable pharmacokinetics are priorities
• Any use case where cycles or periods of discontinuation are planned: enanthate clears in 3 to 4 weeks, undecanoate takes many months to wash out
• Patients who want to titrate dose based on blood work and symptoms: adjustments take effect quickly
• Bodybuilding and performance enhancement: the ability to control dose week-to-week is essential
• Patients who tolerate injections and are comfortable with weekly or twice-weekly administration

Choose testosterone undecanoate for:

• TRT patients who have difficulty with frequent injections (needle phobia, travel, compliance issues)
• Patients managed by a clinic that administers injections in-office (the large volume and REMS requirements in the US mean many patients receive Aveed at the prescribing clinic)
• Patients where consistent compliance with a weekly injection schedule is not realistic
• Situations where simplicity of a quarterly schedule outweighs the pharmacokinetic disadvantages

Blood test timing implications:

• Enanthate users should always note which day of the injection cycle their blood was drawn. Trough testing is the gold standard for safety monitoring.
• Undecanoate users must record the exact date of the last injection when submitting blood work, as the interpretation of testosterone, free testosterone, and oestradiol levels is entirely dependent on where in the long injection cycle the draw occurred.

When undecanoate is clearly not appropriate:

• Any planned cycle with a defined end date and PCT
• When rapid dose adjustment is needed (e.g., side effect management)
• Performance enhancement at supraphysiological doses: 1,000 mg every 10 to 14 weeks is a fixed dose with no flexibility